trending Market Intelligence /marketintelligence/en/news-insights/trending/v92fatImYst4d5krUiRB2w2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Soleno Therapeutics to raise $16.5M via placement

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Soleno Therapeutics to raise $16.5M via placement

Soleno Therapeutics Inc. is selling 10,272,375 units to certain institutional and accredited investors to raise about $16.5 million in gross proceeds.

The units are priced at $1.60625 each and are made up of a common share worth $1.60 and a warrant to buy an additional 0.05 of the company's stock at 0.625 cents apiece, equating to a price of $2 for each one whole share.

The offering, expected to close Dec. 21, will help the biopharmaceutical company meet its clinical trial expenses, which include its ongoing Destiny phase 3 study of medicine Diazoxide Choline to treat a rare and inherited neurobehavioral/metabolic disorder known as Prader-Willi syndrome.

Roth Capital Partners LLC is acting as the company's sole placement agent for the private placement, which is led by bioscience investment firm Abingworth LLP and supported by certain existing investors of the company, including Oracle Investment Management Inc. and entities associated with Jack Schuler and Ernest Mario, the board chairman of Soleno.

In relation to the offering, Abingworth nominated Andrew Sinclair to be appointed as a class I director to Soleno's board, effective upon the closing of the offering and with a term ending at the 2021 annual meeting of stockholders. Sinclair is a partner and portfolio manager at Abingworth.

Concurrent to Sinclair's appointment, Rajen Dalal submitted his resignation as a director from Soleno's board, effective Jan. 1, 2019. His resignation was not the result of any disagreement with Soleno's operations, policies or practices.